ERG positive PIN-like lesions without atypia: a retrograde colonisation of glands by invasive carcinoma instead of a preneoplasic lesion?

2018 ◽  
Author(s):  
Alexandre Serantes Combo ◽  
JOSÉ A. ORTIZ REY
Keyword(s):  
Invasive Carcinoma

Thirty Year Old Female Presented with Nipple Destruction: A Case Report

2019 ◽  
Vol 11 (1) ◽  
pp. 81-83
Author(s):  
Md Mustafizur Rahman ◽  
Nadim Ahmed ◽  
Sami Ahmad ◽  
Shoaeb Imtiaz Alam ◽  
Mohammad Rashedul Hassan ◽  
...  
Keyword(s):  
Invasive Carcinoma ◽  
Paget’S Disease ◽  
Radical Mastectomy ◽  
Paget's Disease ◽  
College Hospital ◽  
Rare Type ◽  
Medical College ◽  
Ductal Cell ◽  
Areola Complex

Paget’s disease of the breast is a rare type of cancer of the nipple–areola complex and that is often associated with an underlying in situ or invasive carcinoma. It is often misdiagnosed as eczema of breast and treatment is delayed. Here we present a case where a 30 year old female presented with itching ulceration and destruction of her left nipple. She was treated initially by local physicians by applying local ointments but as her condition did not improve she was admitted to department of surgery Shaheed Suhrawardy Medical College hospital where she was diagnosed as Paget’s disease with infiltrating ductal cell carcinoma. She underwent modified radical mastectomy with axillary clearance and referred to oncology department for further management. J Shaheed Suhrawardy Med Coll, June 2019, Vol.11(1); 81-83

Disease-free long survival after stump recurrence and reoperation of pancreatic IPMN with invasive carcinoma

Chirurgia ◽  
2019 ◽  
Vol 32 (3) ◽  
Author(s):  
Emanuele Santoro ◽  
Paolo Visca ◽  
Roberto Santoro ◽  
Pietro Mancini ◽  
Eugenio Santoro
Keyword(s):  
Invasive Carcinoma ◽  
Long Survival ◽  
Disease Free

scholarly journals Pre-Operative Imaging and Pathological Diagnosis of Localized High-Grade Pancreatic Intra-Epithelial Neoplasia without Invasive Carcinoma

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 945
Author(s):  
Ryota Sagami ◽  
Kentaro Yamao ◽  
Jun Nakahodo ◽  
Ryuki Minami ◽  
Masakatsu Tsurusaki ◽  
...  
Keyword(s):  
Pancreatic Duct ◽  
Invasive Carcinoma ◽  
Current Knowledge ◽  
Precancerous Lesions ◽  
Ductal Adenocarcinoma ◽  
Pancreatic Ducts ◽  
High Grade ◽  
Cytologic Examination ◽  
Imaging Characteristics ◽  
Retention Cysts

Pancreatic ductal adenocarcinoma (PDAC) arises from precursor lesions, such as pancreatic intra-epithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN). The prognosis of high-grade precancerous lesions, including high-grade PanIN and high-grade IPMN, without invasive carcinoma is good, despite the overall poor prognosis of PDAC. High-grade PanIN, as a lesion preceding invasive PDAC, is therefore a primary target for intervention. However, detection of localized high-grade PanIN is difficult when using standard radiological approaches. Therefore, most studies of high-grade PanIN have been conducted using specimens that harbor invasive PDAC. Recently, imaging characteristics of high-grade PanIN have been revealed. Obstruction of the pancreatic duct due to high-grade PanIN may induce a loss of acinar cells replaced by fibrosis and lobular parenchymal atrophy. These changes and additional inflammation around the branch pancreatic ducts (BPDs) result in main pancreatic duct (MPD) stenosis, dilation, retention cysts (BPD dilation), focal pancreatic parenchymal atrophy, and/or hypoechoic changes around the MPD. These indirect imaging findings have become important clues for localized, high-grade PanIN detection. To obtain pre-operative histopathological confirmation of suspected cases, serial pancreatic-juice aspiration cytologic examination is effective. In this review, we outline current knowledge on imaging characteristics of high-grade PanIN.

scholarly journals SEMA6D Expression and Patient Survival in Breast Invasive Carcinoma

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Dongquan Chen ◽  
Yufeng Li ◽  
Lizhong Wang ◽  
Kai Jiao
Keyword(s):  
Breast Cancer ◽  
Expression Profile ◽  
Heart Development ◽  
Invasive Carcinoma ◽  
Patient Survival ◽  
The Cancer Genome Atlas ◽  
Breast Cancer Patients ◽  
Genomic Expression ◽  
Cancer Genome Atlas ◽  
Public Datasets

Breast cancer (BC) is the second most common cancer diagnosed in American women and is also the second leading cause of cancer death in women. Research has focused heavily on BC metastasis. Multiple signaling pathways have been implicated in regulating BC metastasis. Our knowledge of regulation of BC metastasis is, however, far from complete. Identification of new factors during metastasis is an essential step towards future therapy. Our labs have focused on Semaphorin 6D (SEMA6D), which was implicated in immune responses, heart development, and neurogenesis. It will be interesting to know SEMA6D-related genomic expression profile and its implications in clinical outcome. In this study, we examined the public datasets of breast invasive carcinoma from The Cancer Genome Atlas (TCGA). We analyzed the expression of SEMA6D along with its related genes, their functions, pathways, and potential as copredictors for BC patients’ survival. We found 6-gene expression profile that can be used as such predictors. Our study provides evidences for the first time that breast invasive carcinoma may contain a subtype based on SEMA6D expression. The expression of SEMA6D gene may play an important role in promoting patient survival, especially among triple negative breast cancer patients.

Disease Spectrum of Intraductal Papillary Mucinous Neoplasm With an Associated Invasive Carcinoma

Pancreas ◽  
2013 ◽  
Vol 42 (8) ◽  
pp. 1267-1274 ◽  
Author(s):  
Mee Joo Kang ◽  
Kyoung Bun Lee ◽  
Jin-Young Jang ◽  
Wooil Kwon ◽  
Jae Woo Park ◽  
...  
Keyword(s):  
Intraductal Papillary Mucinous Neoplasm ◽  
Invasive Carcinoma ◽  
Mucinous Neoplasm ◽  
Disease Spectrum

Clinicopathological Follow-up of Breast DCIS Diagnosed on Biopsies: A Single Institutional Study of 575 Patients

2021 ◽  
pp. 106689692110120
Author(s):  
Mingfei Yan ◽  
Phillip Bomeisl ◽  
Hannah Gilmore ◽  
Aparna Harbhajanka
Keyword(s):  
Lymph Node ◽  
Axillary Lymph Node ◽  
Invasive Carcinoma ◽  
Ductal Carcinoma ◽  
Univariate Analysis ◽  
Her2 Status ◽  
Axillary Lymph ◽  
Her2 Amplification ◽  
Therapeutic Implications ◽  
Microinvasive Carcinoma

Stratifying ductal carcinoma in situ (DCIS) patients into different upgrading risk groups is important in exploiting more precise therapeutic options. Evaluation of estrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/HER2) status and axillary lymph node metastatic status for DCIS and their upgraded invasive counterparts can also provide diagnostic and therapeutic implications. We retrospectively studied 575 patients with first-time diagnosis of DCIS on biopsies, and followed up their final diagnosis, ER/PR/HER2 status, and axillary lymph node involvement on excisions. As a result, biopsy-diagnosed DCIS had an overall 19.1% risk to be upgraded on subsequent excisions, with 4.7% being upgraded to microinvasive carcinoma (pT1mi) and 14.4% to overt invasive carcinoma (⩾pT1a). Factors significantly associated with higher upgrading risk on multivariate analysis include biopsy guidance by ultrasound ( P <.001), DCIS with suspicious microinvasion ( P < .001), and DCIS diagnosed in left breast ( P = .026). DCIS diagnosed in younger patients (⩽40 years old) or DCIS with high nuclear grade showed higher upgrading risk only on univariate analysis. About 80% ER + /PR + and ER−/PR− DCIS remained the same ER/PR status after being upgraded, and ER + /PR −  DCIS had the highest risk (63.6%) of having HER2 amplification in upgraded invasive carcinoma. For upgraded DCIS, microinvasive carcinoma was more likely to have HER2 amplification (50%) than overt invasive carcinoma (29.5%). Besides, pure DCIS had a low risk of axillary lymph node macrometastasis (0.74%), while the risk increased in DCIS with microinvasion (4.4%) and was highest in overt invasive carcinoma (14.7%). The findings of this study are clinically relevant with respect to criteria that might be used in selecting patients for de-escalation trials.

Sign in / Sign up

Export Citation Format

Share Document